| Oct 18 |
Three-year Results for EYLEA HD® (aflibercept) Injection 8 mg Demonstrate Continued Durable Vision Gains and Anatomic Improvements with Extended Dosing Intervals in Patients with Diabetic Macular Edema
|
| Oct 17 |
Regeneron price target lowered to $1,137 from $1,200 at Truist
|
| Oct 16 |
Is Regeneron Pharmaceuticals, Inc. (REGN) the Best High Growth NASDAQ Stock That is Profitable in 2024?
|
| Oct 12 |
Weight loss drugs have one big issue; these companies want to fix it
|
| Oct 10 |
Here's How Much $100 Invested In Regeneron Pharmaceuticals 15 Years Ago Would Be Worth Today
|
| Oct 10 |
What the Options Market Tells Us About Regeneron Pharmaceuticals
|
| Oct 10 |
Kodiak Counts on Tarcocimab Eye Disease Program Despite Setbacks
|
| Oct 10 |
Regeneron (REGN) Loses -11.32% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
|
| Oct 8 |
Regeneron Gains 13.5% Year to date: How to Play the Stock?
|
| Oct 7 |
Regeneron sees IPR&D impact of about $0.43/share on Q3 income
|
